The World Health Organization (WHO) has unveiled its Global Tuberculosis (TB) Report 2026, painting a sobering picture of a preventable epidemic. Throughout 2025, an estimated 10.6 million individuals contracted the disease, with 1.13 million succumbing to it. These figures solidify TB’s status as the world’s deadliest single infectious agent, serving as a stark reminder that the fight against this pathogen remains far from over.

A Mixed Legacy of Progress and Stagnation

Despite the grim mortality rates, the data indicates a downward trend in the global TB burden. A significant milestone in mortality reduction was finally achieved in 2025, though it arrived five years behind the original schedule. The incidence rate dropped to 129 per 100,000 people—a 1.6% improvement over 2024—while mortality rates saw a 4% decline. Tereza Kasaeva, Director of the WHO Department for HIV, Tuberculosis, Hepatitis and Sexually Transmitted Infections, noted that these results prove political will and community-led initiatives can drive meaningful change.

However, experts warn against complacency. Cassandra Kelly-Cirino of the International Union Against Tuberculosis and Lung Disease highlighted that the 14% drop in incidence since 2015 is woefully short of the 50% target. She emphasized that current efforts are insufficient to meet 2030 and 2035 goals, particularly as international donor funding plummeted by 14%—dropping from US$ 1.1 billion to US$ 0.94 billion in 2025—largely due to austerity measures in the U.S. and G7 nations.

The Widening Funding Gap

While economic powerhouses like India, China, and Brazil have stepped up domestic spending to fill the void, low-income nations, particularly across Africa, are struggling. Melino Ndayizigiye of Partners In Health described the human cost of these cuts: “I’ve witnessed the devastating impact firsthand. TB screening has plummeted, and we have lost hundreds of frontline workers, leading to critical disruptions in supply chains and essential health services.”

Technological Breakthroughs and Future Hurdles

  • Treatment Innovation: The adoption of six-month regimens for rifampicin-resistant TB surged, covering 42% of patients in 2025 compared to just 3% in 2023.
  • Diagnostic Advancements: Rapid molecular testing is becoming the standard, with 59% of new cases diagnosed via WHO-recommended rapid tests in 2025.
  • Vaccine Pipeline: Hope is building with 12 vaccine candidates currently in various stages of clinical trials.

Despite these technical strides, the gap in care remains profound. TB advocate Nandita Venkatesan pointed out that less than half of those with drug-resistant TB received the specialized treatment necessary for a cure. Furthermore, with only 44% of the global population having access to social protection benefits, the underlying socio-economic drivers of the epidemic remain largely unaddressed. Experts agree that only a combination of sustained investment, global solidarity, and universal social protection will finally bring this crisis to an end.